Plasmamonitorering af neuroleptika i praksis

References

• Dahl S G. Plasma level monitoring of antipsychotic drugs. Clinical utility. Clin Pharmacokin 1986; 11: 36–61
   Google Scholar
• Brøsen K, Gram L F. Pharmacokinetic and clinical significance of genetic variability in psychotropic drug metabolism. Clinical pharmacology in psychiatry. From molecular studies to clinical reality, S G Dahl, L F Gram. Springer- Verlag, Berlin, Heidelberg 1989; 192–200, (Psycho-pharmacology series 7)
   Google Scholar
• Macleod S M, Soldin S J. Determinants of drug disposition in man. Clin Biochem 1986; 19: 67–71
   Google Scholar
• Jørgensen A. Metabolism and pharmacokinetics of antipsychotic drugs. Progress in drug metabolism, J W Bridges, L FS Chasseaud. Taylor and Francis, London 1986; 9: 111–74
   Google Scholar
• Balant-Gorgia A E, Balant L. Antipsychotic drugs. Clinical pharmacokinetics of potential candidates for plasma concentration monitoring. Clin Pharmacokin 1987; 13: 65–90
   PubMed Web of Science ®Google Scholar
• Axelsson R. Plasma level monitoring of neuroleptic drugs. A way to improve the treatment of psychotic patients. Treatment with neuroleptics, K Strandberg, B Beermann, G Lönnerhol. National Board of Health and Welfare, Drug Information Committee, Sweden 1990; 1: 39–51
   Google Scholar
• Larsen N E, Hansen L B. Prediction of the optimal perphenazine decanoate dose based on blood samples drawn within the first weeks. Ther Drug Monit 1989; 11: 242–6
   Google Scholar
• Mårtensson E. Interindividual variation in the kinetics of neuroleptic drugs. Sweden. Treatment with neuroleptics, K Strandberg, B Beermann, G Lönnerhol. National Board of Health and Welfare, Drug Information Committee, Sweden 1990; 1: 9–17
   Google Scholar
• Garver D L. Neuroleptic drug levels in erythrocytes and in plasma: implication for therapeutic drug monitoring. Clinical pharmacology in psychiatry. From molecular studies to clinical reality, S G Dahl, L F Gram. Springer-Verlag, Berlin, Heidelberg 1989; 244–56, (Psychopharmaco-logy series 7)
   Google Scholar
• Dahl S G, Hals P A. Pharmacokinetic and pharmacodynamic factors causing variability in response to neuroleptic drugs. Clinical pharmacology in psychiatry. Selectivtiy in psychotropic drug action - promises or problems?, S G Dahl, L F Gram, S M Paul, W Z Potter. Springer, Berlin, Heidelberg, New York 1987; 3: 266–74
   Google Scholar
• Vozeh S. Cost-effectiveness of therapeutic drug monitoring. Clin Pharmacokin 1987; 13: 131–40
   PubMedGoogle Scholar
• Destache C J, Meyer S K, Bittner M J, Hermann K G. Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides: a cost-benefit analysis. Ther Drug Monit 1990; 12: 419–26
   PubMed Web of Science ®Google Scholar
• Wing S D, Duff H J. The impact of a therapeutic drug monitoring program for phenytoin. Ther Drug Monit 1989; 11: 32–7
   Google Scholar
• Van Putten T, Marder S R, Wirshing W C, Aravagiri M, Chabert N. Neuroleptic plasma levels. Schizophren Bull 1991; 17: 197–216
   PubMed Web of Science ®Google Scholar
• Dahl S G. Pharmacokinetics of neuroleptic drugs and the utility of plasma level monitoring. Psyc-hopharmacol Series 1988; 5: 34–46
   Google Scholar
• Baldessarini R J, Cohen B M, Teicher M H. Sig-nifiance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988; 45: 79–91
   PubMed Web of Science ®Google Scholar
• Brown W A, Laughren T, Chisholm E, Williams B W. Low serum neuroleptic levels predict relapse in schizophrenic patients. Arch Gen Psychiatry 1982; 39: 998–1000
   PubMed Web of Science ®Google Scholar
• Wistedt B, Jorgensen A, Wiles D. A depot neuroleptic withdrawal study: plasma concentration of fluphenazine and flupenthixol and relapse frequency. Psychopharmacology 1982; 78: 301–4
   Google Scholar
• Marder S R, Van Putten T, Aravagiri M. Plasma level monitoring for maintenance neuroleptic therapy. Clinical pharmacology in psychiatry. From molecular studies to clinical reality, S G Dahl, L F Gram. Sprin-ger-Verlag, Berlin Heidelberg 1989; 269–79, (Psychopharmacology series 7)
   Google Scholar
• Workshop group. Treatment with neuroleptics. Recommendations from the group. Sweden National Board of Health and Welfare, K Strandberg, B Beermann, G Lönnerhol. Drug Information Committee. 1990; 1: 143–54
   Google Scholar
• Knudsen P, Hansen L B, Højholdt K, Larsen N E. Long-term depot neuroleptic treatment with perphenazine decanoate. I. Efficacy and side effects in a 12 month study of 42 drug monitored psychotic patients. Acta Psychiatr Scand 1985; 322(Suppl)29–40
   Google Scholar
• Kane J M. Compliance issues in outpatient treatment. J Clin Psychopharmacol 1985; 5(Suppl 3)
   Google Scholar
• Young J L, Zonana H V, Shepler L. Medication noncompliance in schizophrenia: codification and update. Bull Am Acad Psychiatry Law 1986; 14(2)
   Google Scholar
• Hansen L B, Larsen N E. Metabolic interaction between perphenazine and disulfiram. Lancet 1982; 2: 1472
   PubMed Web of Science ®Google Scholar
• Aaes-Jørgensen T, Liedholm H, Melander A. Influence of food intake on the bioavailability of zuc-lopenthixol. Drug Nutr Interact 1987; 5: 157–160
   Google Scholar
• Bergman U, Sjöqvist F. The new pharmacogenetics. Implications for the prescribing of neuroleptic drugs and for therapeutic drug monitoring. Treatment with neuroleptics, K Strandberg, B Beermann, G Lönnerhol. National Board of Health and Welfare, Drug Information Committee, Sweden 1990; 1: 19–26
   Google Scholar
• Altamura A C. Drug-resistance phenomena in major psychoses. Their discrimination and causal mechanisms. Clin Neuropharmacol 1990; 13(Suppl 1)1–15
   Google Scholar
• Farde L. PET-determination of dopamine receptor binding in patients treated with antipsychotic drugs. Implications for neuroleptic dose regimens. Treatment with neuroleptics, K Strandberg, B Beermann, G Lönnerhol. National Board of Health and Welfare, Drug Information Committee, Sweden 1990; 1: 53–63
   Google Scholar
• Knudsen P, Hansen L B, Larsen N E. Perphenazine decanoate in sesame oil vs. perphenazine enant-hate in sesame oil. A comparative study of phar-makokinetic properties and some clinical implications. Acta Psychiatr Scand 1985; 322(Suppl)11–14
   Google Scholar
• Rosenberg R. God psykofarmakologisk praksis. Nord J Psychiatriy 1992; 46(Suppl 26)35–38
   Google Scholar